Recently, it has been established that androgen receptors are present in higher-stage tumors regardless of gender, and the assumption that AR-positive RCC has intratumoral steroidogenesis and that antiandrogen therapy can lead to tumor suppression has been studied. The gene discussed is AR; the disease is renal cell carcinoma.